R

ise and shine, another busy day is on the way. Most every day is busy, though, is it not? Well, no matter. Busy is good, as they say. After all, consider the alternatives. While you ponder, please join us for our ritual cup of stimulation, which is a much-needed boost this morning, thanks to a growing to-do list of meetings and phone calls and deadlines — oh my! Meanwhile, we have gathered a few items of interest to help you along. Hopefully, this will be equally stimulating. Hope you conquer the world and stay in touch …

A new bill would make Ontario the first Canadian province to require public disclosure of payments that drug and medical device makers make to doctors, The Toronto Star reports. In June, companies voluntarily released data showing they had paid nearly $50 million to Canadian health-care professionals and organizations in 2016, but the disclosure was criticized for lacking payments to individual doctors, prompting calls for mandatory reporting.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hmmm – from above – Point: “Aurobindo accomplished this with an R&D budget that is half to a third the size of those other companies.” and counter-point: “Aurobindo Pharma received a Form 483 report after FDA inspectors found various manufacturing problems at its facility in Chitkul Village,”
    Mayhaps they also save on manufacturing quality as well to let them make ‘lesser product at a lesser price’ or not …. sheer coincidence, I am sure.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy